Skip to Main Content

Author Details

Amrita Basu
University of California San Francisco
2018
19
7
PMIDPaper TitleJournal TitlePublished Year
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
37061003TFCP2 is a transcriptional regulator of heparan sulfate assembly and melanoma cell growth.J Biol Chem2023
36689092Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.Breast Cancer Res Treat2023
37061003TFCP2 is a transcriptional regulator of heparan sulfate assembly and melanoma cell growth.J Biol Chem2023
37384294Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes.Front Oncol2023
34785506Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4<sup>+</sup> Th1 Responses and Potential Use as a Cancer Vaccine.Cancer Immunol Res2022
35710296Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.J Immunother Cancer2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
33626407Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.Semin Cancer Biol2022
34785506Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4<sup>+</sup> Th1 Responses and Potential Use as a Cancer Vaccine.Cancer Immunol Res2022
34437890An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models.J Mol Biol2022
35710296Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma.J Immunother Cancer2022
35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer Cell2022
33626407Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities.Semin Cancer Biol2022
34437890An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models.J Mol Biol2022
33412308Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.Mol Ther2021
34012451Differentiation and Regulation of T<sub>H</sub> Cells: A Balancing Act for Cancer Immunotherapy.Front Immunol2021
33957704Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.Cancer2021
33412308Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.Mol Ther2021
34899753Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Front Immunol2021
34899753Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Front Immunol2021
34012451Differentiation and Regulation of T<sub>H</sub> Cells: A Balancing Act for Cancer Immunotherapy.Front Immunol2021
33957704Incorporation of Patient-Reported Outcomes Measurement Information System to assess quality of life among patients with breast cancer initiating care at an academic center.Cancer2021
31552690Conserved core tryptophans of FnII domains are crucial for the membranolytic and chaperone-like activities of bovine seminal plasma protein PDC-109.FEBS Lett2020
32078367Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes.JCO Clin Cancer Inform2020
32157934Multimodal approaches to improve immunotherapy in breast cancer.Immunotherapy2020
31552690Conserved core tryptophans of FnII domains are crucial for the membranolytic and chaperone-like activities of bovine seminal plasma protein PDC-109.FEBS Lett2020
33463942Strategies to Combat Human Epidermal Growth Factor Receptor 2 (HER2) Resistance in HER2-Positive Breast Cancer.Crit Rev Oncog2020
32078367Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes.JCO Clin Cancer Inform2020
33463942Strategies to Combat Human Epidermal Growth Factor Receptor 2 (HER2) Resistance in HER2-Positive Breast Cancer.Crit Rev Oncog2020
32157934Multimodal approaches to improve immunotherapy in breast cancer.Immunotherapy2020
31202361Immunotherapy in breast cancer: Current status and future directions.Adv Cancer Res2019
31475002Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.Front Immunol2019
31202361Immunotherapy in breast cancer: Current status and future directions.Adv Cancer Res2019
31475002Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.Front Immunol2019
29796172Oncodriver inhibition and CD4<sup>+</sup> Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.Oncotarget2018
29796172Oncodriver inhibition and CD4<sup>+</sup> Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.Oncotarget2018
  • 1 - 38 of 38

Recommended Authors

Chiara Corti
University of Milano
Career Start Year 2017
Number of shared co-authors 1
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 2
Katie M Campbell
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2014
Number of shared co-authors 0
Davide Bedognetti
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2010
Number of shared co-authors 3
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 0
Jianying Zhang
City of Hope National Medical Center
Career Start Year 2009
Number of shared co-authors 0
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 0
Benjamin G Vincent
UNC School of Medicine, The University of North Carolina at Chapel Hill
Career Start Year 2008
Number of shared co-authors 3
Bora Lim
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 0
Sara M Tolaney
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Minya Pu
University of California
Career Start Year 2003
Number of shared co-authors 0
Mark E Smolkin
University of Virginia
Career Start Year 2002
Number of shared co-authors 0
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Career Start Year 2002
Number of shared co-authors 0
Ivy X Chen
Massachusetts General Hospital
Career Start Year 2002
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 1
Ningyan Zhang
Stem Cell Translational Research Center of Tongji Hospital, Tongji University
Career Start Year 2000
Number of shared co-authors 1
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 2
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 3
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 3
Steven J Isakoff
Massachusetts General Hospital
Career Start Year 1995
Number of shared co-authors 3
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 2
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Career Start Year 1993
Number of shared co-authors 0
Ramona F Swaby
Merck & Co., Inc.
Career Start Year 1991
Number of shared co-authors 0
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 2
Joan Albanell
Hospital del Mar Research Institute
Career Start Year 1990
Number of shared co-authors 0
Alberto Zambelli
IRCCS Humanitas Research Hospital
Career Start Year 1987
Number of shared co-authors 0
Elizabeth M Jaffee
Convergence Institute, Johns Hopkins University
Career Start Year 1985
Number of shared co-authors 1
Eric P Winer
Dana-Farber Cancer Institute
Career Start Year 1985
Number of shared co-authors 2

Collaborators

Laura J Van't Veer
University of California San Francisco
Co-authored papers 4
Christina Yau
University of California San Francisco
Co-authored papers 3
Denise M Wolf
University of California San Francisco
Co-authored papers 2
Minetta C Liu
Co-authored papers 2
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 1
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 1
Jeanine M Genkinger
Mailman School of Public Health, Columbia University
Co-authored papers 1
Alex A T Bui
Co-authored papers 1
Stephanie S Yee
University of Pennsylvania
Co-authored papers 1
Jack DiGiovanna
Swiss Federal Institute of Technology (EPFL)
Co-authored papers 1
Wenjin Jim Zheng
University of Texas Health Science Center at Houston
Co-authored papers 1
Warren A Kibbe
Duke Clinical Research Institute, Duke University
Co-authored papers 1
William F Symmans
Co-authored papers 1
Claudine Isaacs
Co-authored papers 1
Joel Saltz
Stony Brook University
Co-authored papers 1
Alexander D Borowsky
University of California Davis Health
Co-authored papers 1
James E Korkola
Co-authored papers 1
Jill S Barnholtz-Sloan
National Cancer Institute
Co-authored papers 1
Dana E Rollison
Moffitt Cancer Center
Co-authored papers 1
Judy C Boughey
Mayo Clinic
Co-authored papers 1
Travis Gerke
The Prostate Cancer Clinical Trials Consortium
Co-authored papers 1
Jennifer B Permuth
Moffitt Cancer Center
Co-authored papers 1
Elizabeth A Shenkman
University of Florida
Co-authored papers 1
Lisa B Mirel
National Center for Health Statistics, Centers for Disease Control and Prevention
Co-authored papers 1
Marta Induni
Cancer Registry of Greater California
Co-authored papers 1
Feng Hsiao
University of California San Francisco
Co-authored papers 1
Alex A T Bui
University of California Los Angeles
Co-authored papers 1
Montserrat Garcia-Closas
National Cancer Institute
Co-authored papers 1
Mary L Disis
University of Washington Medicine Cancer Vaccine Institute, University of Washington
Co-authored papers 1
Emanuel F Petricoin
Center for Applied Proteomics and Molecular Medicine, George Mason University
Co-authored papers 1
Release 1.2